
Sign up to save your podcasts
Or


"First, do no harm" is a popular saying amongst those involved in the healthcare, medicine, or bioethics field, and is a basic principle taught in health-related courses. To faithfully follow this principle, a health professional should help their patients by recommending tests or treatments for which the potential benefits outweigh the risks of harm.
In this episode, Michael Fronstin, Global Head of Clinical Regulatory & Safety Research and Consulting and Susanne Faber, Director, Advanced Methodologies Clinical Regulatory & Safety, both from Cerner Enviza, share the value and importance of real-world datasets containing de-identified, person-centric, longitudinal records to monitor safety.
On receiving news of a health concern there is an immediate thirst for knowledge to understand the condition, the care, and treatment options available.
As a healthcare professional assesses the health status of a person, it may be decided that prescribing a therapeutic drug is the best course of action. These treatments are assigned systematically, not randomly, to achieve an outcome goal. A much smaller number of healthcare professionals may discuss the opportunity for a person to participate in a clinical trial to find new and improved ways to treat, prevent or diagnose different illnesses. Clinical trials generally seek to isolate the pure treatment effect and do so by eliminating or balancing people across comparison groups. These care options are mainly assigned randomly.
In this episode, Jeremy Brody, Head of Global Strategy at Cerner Enviza, discusses when and how industry leaders are embracing both clinical research and real-world data to make care and treatments decisions.
Patients are the most important constituent in clinical development and provide the necessary information to assess the safety and efficacy of new medicines. Participation in clinical research requires informed consent. The importance of informed consent cannot be overstated – participants must completely understand all that is involved in a clinical trial prior to providing their signed consent.
In this episode, Andrea Valente, Chief Executive Officer of ClinOne, shares her thoughts on consent, informed consent, and how the principles of consent management is an important emerging approach in clinical research – a topic of particular interest as we continue to hear stories in the industry literature concerning complicated study designs, variability in literacy levels and cultural diversity in clinical research.
Access to relevant and trustworthy data to make accurate and timely healthcare decisions is critical. Cohesive industry collaboration is key to removing barriers to data access and increasing adoption of sensors in health science. In this episode, Jennifer Goldsack, Chief Executive Officer of non-profit Digital Medicine Society (DiMe) discusses a multistakeholder Sensor Data Integration collaboration designed to provide clear direction on how sensor data can fulfill its potential to enhance patient lives.
Clinical research is the study of health and illness in people. It's about putting people – the participants and volunteers – at the center of finding out if a new treatment is safe and effective. What clinical research and clinical research participation means is often discussed and frequently shared. In this episode, Ken Getz, Executive Director and Professor of Tufts Center for the Study of Drug Development (CSDD), and Elisa Cascade, Chief Product Officer of Science 37, offer insights on the realities and complexities encountered in conducting clinical research around the world.
International Clinical Trials Day, celebrated each year on May 20th, commemorates the day that James Lind began the first randomized clinical trial in 1747. It also provides an opportunity to recognize and thank everyone involved in clinical research. In this episode, Bruce Hellman, Co-founder and Chief Patient Officer at uMotif offers a practical perspective on what it means to be patient-centric in trial design - including diversity, digital literacy, and the availability of hybrid clinical trial models.
The use of mobile devices, social media, wearables, and other biosensors continues to expand year on year. The curation and analyses of health-related data is accelerating, and these data provide the potential to answer questions previously thought infeasible. When a researcher is seeking answers to a health question, when is it appropriate to use real-world data (RWD) and when it is appropriate to conduct clinical research? In this episode, Dr. Susan Dallabrida, CEO, SPRIM Consulting, and Dr. Carla Rodriguez-Watson, Director of Research, Reagan-Udall Foundation for the FDA, share their extensive experiences with RWD and real-world evidence (RWE).
The European Union (EU) has been on a path to harmonize the clinical trial process and requirements since 2004 starting with the Directive. The next step came 10 years later, in 2014, with the Clinical Trial Regulation (CTR). This year, as of January 31, the Clinical Trials Information System (CTIS) went live and supports the flow of information between clinical trial sponsors, EU Member States, European Economic Area (EEA) countries and the European Commission. In this episode, Marieke Meulemans from GCP Central and Sebastian Payne from Deloitte share how clinical research and patient health in the EU will benefit from the streamlined regulatory processes and a new portal.
There are more than seven thousand rare diseases in the world – 95% of which have no known treatment. The term rare diseases is a cruel misnomer – in fact they aren't that rare, and importantly, the definition of what constitutes a rare disease differs by country. To raise awareness, Rare Disease Day is recognized on the last day of February annually. In this episode, industry leaders Joan Chambers, senior director of marketing and outreach at CISCRP, and Scott Schliebner, executive VP and chief strategy officer at M&B Sciences, discuss the importance of improving access to treatment and medical representation for individuals with rare diseases and their families.
Life sciences organizations face intense pressure to speed clinical trials while boosting operational efficiencies to battle the rising costs of drug development. So what does the future of clinical trials look like?
In this episode, Dr. Avi Kulkarni, senior vice president of research and development at Cognizant, and Henry McNamara, senior vice president and GM of Oracle Health Sciences, share their views on what has been accomplished over the past 10 years, current trends, and their outlook for the future.
From the publisher's feed